Literature DB >> 23404256

miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells.

Peter Dynoodt1, Reinhart Speeckaert, Olivier De Wever, Inès Chevolet, Lieve Brochez, Jo Lambert, Mireille Van Gele.   

Abstract

MicroRNAs (miRNAs) are post-transcriptional modulators of gene expression which play important roles in tumorigenesis and cancer metastasis. Since they are often highly deregulated in various types of cancer, miRNAs may be effective treatment targets. miRNA profiling studies of melanoma have led to the identification of several tumor suppressor miRNAs. One of these include miR-145, although functional data proving its specific function are limited. Therefore, in this study, we examined the expression levels of miR-145 in three melanoma cell lines (BLM, FM3P and WM793). Additional gain-of-function experiments revealed that miR-145 exerts an anti-proliferative effect in the primary, non-invasive melanoma cell line, WM793, whereas cell migration and the invasive potential of metastatic melanoma cells was suppressed following transfection with miR-145 mimics. In order to investigate the mechanisms by which miR-145 exerts its invasion suppressor function, we examined the expression level of target genes [fascin homolog 1 (FSCN1), myosin‑Va (MYO5A and SOX9] and that of an indirect target (RAB27A) following the overexpression of miR-145. The results showed that SOX9, MYO5A and RAB27A were not involved in the biological effects caused by miR-145 mimics. Surprisingly, we discovered that miR-145 in melanoma, in contrast to many other tumor types, does not necessarily act via the target, FSCN1, since the downregulation of FSCN1 did not inhibit cell proliferation or migration but, on the contrary, increased cell invasion in two out of the three melanoma cell lines examined. Our in vitro data is in accordance with previously reported in vivo data describing the low expression of FSCN1 in malignant melanomas when compared to dysplastic nevi, suggesting that the expression of FSCN1 decreases as the formation and progression stage of melanoma advances. In conclusion, our data provide evidence that miR-145 is an invasion suppressor in metastatic melanoma cells. Despite the fact that it remains unclear which genes or pathways are regulated by miR-145 in melanoma, miR-145 may serve as a useful therapeutic agent in melanoma when re-expressed in situ.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404256     DOI: 10.3892/ijo.2013.1823

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  36 in total

Review 1.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

Review 2.  Epigenetic markers in melanoma.

Authors:  Weimin Guo; Ting Xu; Jonathan J Lee; George F Murphy; Christine G Lian
Journal:  Melanoma Manag       Date:  2015-11-24

Review 3.  An updated review of mechanotransduction in skin disorders: transcriptional regulators, ion channels, and microRNAs.

Authors:  Jing Wang; Yifan Zhang; Ning Zhang; Chuandong Wang; Tanja Herrler; Qingfeng Li
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

4.  Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo.

Authors:  Shunsuke Noguchi; Junya Iwasaki; Minami Kumazaki; Takashi Mori; Kohji Maruo; Hiroki Sakai; Nami Yamada; Kazuyuki Shimada; Tomoki Naoe; Yukio Kitade; Yukihiro Akao
Journal:  Mol Ther       Date:  2013-04-30       Impact factor: 11.454

Review 5.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

6.  MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression.

Authors:  Juanjuan Bai; Zhongling Zhang; Xing Li; Huifan Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 7.  MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.

Authors:  Anita Thyagarajan; Ahmed Shaban; Ravi Prakash Sahu
Journal:  J Pharmacol Exp Ther       Date:  2017-10-20       Impact factor: 4.030

8.  Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma.

Authors:  Yanping Wei; Yuwen Du; Xiaonan Chen; Ping Li; Yuanyuan Wang; Wenqiao Zang; Lindong Zhao; Zhongdong Li; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2014-05-18

Review 9.  Pterygium: an update on pathophysiology, clinical features, and management.

Authors:  Toktam Shahraki; Amir Arabi; Sepehr Feizi
Journal:  Ther Adv Ophthalmol       Date:  2021-05-31

Review 10.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.